Zelira Therapeutics Limited (ZLD:ASX)

3.7¢

right-arrow Created with Sketch. 0 (0%)
MCAP $44.04M
Last trade 16.10pm 17/09/2021 20mins delayed

Latest Announcements

30/08/2021ZLDZelira Therapeutics Limited
195
MCap
30/08/2021 Price SensitivePSZLDZelira Therapeutics Limited
23/08/2021ZLDZelira Therapeutics Limited
30/07/2021 Price SensitivePSZLDZelira Therapeutics Limited
30/07/2021 Price SensitivePSZLDZelira Therapeutics Limited
12/07/2021 Price SensitivePSZLDZelira Therapeutics Limited
05/07/2021ZLDZelira Therapeutics Limited
30/06/2021 Price SensitivePSZLDZelira Therapeutics Limited

Company Overview

Zelira Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. The Company's lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. It is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care product containing cannabinoids and based on the patented technology of blackseed oil and zinc.

ZLD in the news

Zelira Therapeutics (ZLD) reports testing of its oral cannabidiol (CBD) capsules on…
Zelira Therapeutics (ZLD) signs a five-year distribution with Health House International to…
Medicinal cannabis company Zelira Therapeutics (ZLD) is set to distribute its HOPE…
Medical cannabis company Zelira Therapeutics (ZLD) has reported record revenue during the…

Search Previous Announcements